A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
A 46-week, Double-blind, Placebo-controlled, Phase 3 Study With a 6-week Randomized-withdrawal Period to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
A 46-week study to compare the efficacy of relamorelin with that of placebo in participants with diabetic gastroparesis (DG). At the end of the 40-week Treatment Period, participants will either continue on relamorelin or placebo for 6 additional weeks.
Inclusion Criteria:
Exclusion Criteria:
Colorado Springs, Colorado 80909, United States
Metairie, Louisiana 70006, United States
Frederick, Maryland 21701, United States
Wadsworth, Ohio 44281, United States
C.a.b.a., Buenos Aires C1425AGC, Argentina
CABA, Buenos Aires C1419AHN, Argentina
Córdoba, Córdoba Province X5000AAW, Argentina
Rosario, Santa Fe Province S200CFK, Argentina
San Miguel de Tucumán, Tucumán Province 4000, Argentina
Fortaleza, Ceará 60160-230, Brazil
Joinville, Santa Catarina 89201-260, Brazil
Bogotá, Cundinamarca 111111, Colombia
Pereira, Risaralda Department 660002, Colombia
Hyderabad, Andhra Pradesh 500072, India
Ahmedabad, Gujarat 380007, India
Durango, Guillermina 34270, Mexico
Guadalajara, Jalisco 44150, Mexico
Mexico City, Mexico City 11650, Mexico
St-Petersburg, Leningradskaya Oblast' 199106, Russia
Novosibirsk, Novosibirsk Oblast 630117, Russia
Saint Petersburg, Sankt-Peterburg 191015, Russia
Nizhny Novgorod, Volga 603126, Russia
Ivano-Frankivsk, Ivano-Frankivsk Oblast 76018, Ukraine
Chernivtsi, 58001, Ukraine
Dnipro, 49027, Ukraine
Kharkiv, 61039, Ukraine
Kharkiv, 61070, Ukraine
Kyiv, 2002, Ukraine
Kyiv, 3049, Ukraine
Kyiv, 4050, Ukraine
Odesa, 65010, Ukraine
Odesa, 65025, Ukraine
Vinnytsia, 21029, Ukraine